Yoshiaki Usui

Yoshiaki Usui

Auto-generated profile, based on publicly available information

Yoshiaki Usui

Laboratory for Genotyping Development, RIKEN Center for Integrative Medical Sciences, Yokohama, Japan

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2023 in New England Journal of Medicine
Verified
Journal Article
Closed access
YUYoshiaki Usui
Yoshiaki Usui
YTYukari Taniyama
Yukari Taniyama
MEMikiko Endo
Mikiko Endo
YKYuriko N. Koyanagi
Yuriko N. Koyanagi
YKYumiko Kasugai
Yumiko Kasugai
YMYukihide Momozawa
Yukihide Momozawa
Helicobacter pylori infection is a well-known risk factor for gastric cancer. However, the contribution of germline pathogenic variants in cancer-predisposing genes and their effect, when combined with H. pylori infection, on the risk of gastric cancer has not been widely evaluated. We evaluated the association between germline pathogenic variants in 27 cancer-predisposing genes and the risk of gastric cancer in a sample of 10,426 patients with gastric cancer and 38,153 controls from BioBank Japan. We also assessed the combined effect of pathogenic variants and H. pylori infection status on the risk of gastric cancer and calculated the cumulative risk in 1433 patients with gastric cancer and 5997 controls from the Hospital-based Epidemiologic Research Program at Aichi Cancer Center (HERPACC). Germline pathogenic variants in nine genes (APC, ATM, BRCA1, BRCA2, CDH1, MLH1, MSH2, MSH6, and PALB2) were associated with the risk of gastric cancer. We found an interaction between H. pylori infection and pathogenic variants in homologous-recombination genes with respect to the risk of gastric cancer in the sample from HERPACC (relative excess risk due to the interaction, 16.01; 95% confidence interval [CI], 2.22 to 29.81; P = 0.02). At 85 years of age, persons with H. pylori infection and a pathogenic variant had a higher cumulative risk of gastric cancer than noncarriers infected with H. pylori (45.5% [95% CI, 20.7 to 62.6] vs. 14.4% [95% CI, 12.2 to 16.6]). H. pylori infection modified the risk of gastric cancer associated with germline pathogenic variants in homologous-recombination genes. (Funded by the Japan Agency for Medical Research and Development and others.).

28 March 2022 in Leukemia
Verified
Journal Article
Closed access
PDF file
KKKazuaki Kameda
Kazuaki Kameda
SKShinichi Kako
Shinichi Kako
SKSung-Won Kim
Sung-Won Kim
YUYoshiaki Usui
Yoshiaki Usui
KKKoji Kato
Koji Kato
EKEisei Kondo
Eisei Kondo

3 May 2016 in Hematological Oncology
Verified
Journal Article
Closed access
PDF file
KMKosei Matsue
Kosei Matsue
YMYuya Matsue
Yuya Matsue
KKKaoru Kumata
Kaoru Kumata
YUYoshiaki Usui
Yoshiaki Usui
YSYasuhito Suehara
Yasuhito Suehara
MTMasami Takeuchi
Masami Takeuchi

5 September 2022 in Cancer Science
Verified
Journal Article
Open access
YUYoshiaki Usui
Yoshiaki Usui
YIYusuke Iwasaki
Yusuke Iwasaki
Keitaro MatsuoKeitaro Matsuo
Keitaro Matsuo
MEMikiko Endo
Mikiko Endo
YKYoichiro Kamatani
Yoichiro Kamatani
YMYukihide Momozawa
Yukihide Momozawa
The application of advanced molecular technology has significantly expanded lymphoma classification, allowing risk stratification and treatment optimization. Limited evidence suggests the presence of a genetic predisposition in lymphoma, indicating the potential for better individualized clinical management based on a novel lymphoma classification. Herein, we examined the impact of germline pathogenic variants in 27 cancer‐predisposing genes with lymphoma risk and explored the clinical characteristics of pathogenic variant carriers. This study included 2,066 lymphoma patients and 38,153 cancer‐free controls from the Japanese population. Following quality control of sequencing data, samples from 1,982 lymphoma patients and 37,592 controls were further analyzed. We identified 309 pathogenic variants among 4,850 variants in the 27 cancer‐predisposing genes. Pathogenic variants in the following four cancer‐predisposing genes were associated with a high risk of lymphoma: ATM (odds ratio [OR], 2.63; 95% confidence interval [CI], 1.25–5.51; p = 1.06 × 10−2), BRCA1 (OR, 5.88; 95% CI, 2.65–13.02; p = 1.27 × 10−5), BRCA2 (OR, 2.94; 95% CI, 1.60–5.42; p = 5.25 × 10−4), and TP53 (OR, 5.22; 95% CI, 1.43–19.02; p = 1.23 × 10−2). The proportion of carriers of these genes was 1.6% of lymphoma patients. Furthermore, pathogenic variants in these genes were especially associated with a higher risk of mantle cell lymphoma (OR, 21.57; 95% CI, 7.59–61.26; p = 8.07 × 10−9). These results provide novel insights concerning monogenic form into lymphoma classification. Some lymphoma patients may benefit from surveillance and targeted treatment, such as other neoplasms.

13 January 2016 in Leukemia & Lymphoma
Verified
Journal Article
Closed access
PDF file
KFKota Fukumoto
Kota Fukumoto
MFManabu Fujisawa
Manabu Fujisawa
YSYasuto Suehara
Yasuto Suehara
KNKen-Taro Narita
Ken-Taro Narita
YUYoshiaki Usui
Yoshiaki Usui
KMKosei Matsue
Kosei Matsue
To investigate the impact of immunophenotypic complete response [iCR, ≤10−4 multiple myeloma (MM) cells defined by multicolor flow cytometry (MFC)] on survival in patients with MM, we retrospectively analyzed 78 patients that obtained conventional CR at our hospital. Survivals were landmarked at achievement of CR. The rate of stringent CR (sCR) among patients with CR was 88%, and iCR for CR and sCR patients were 44% and 49%, respectively. Achievement of iCR was associated with significantly longer disease-free survival (DFS) not only in CR patients (p = 0.009) but also in sCR patients (p = 0.002), while sCR attainment per se did not have statistically significant impact on DFS (p = 0.06) or overall survival (OS) (p = 0.587). Univariate and multivariate analyses indicated that attainment of iCR was independently associated with longer 2-year DFS in addition to creatinine (≤2.0 mg/dL) and maintenance therapy. This study highlights the importance of pursuing iCR even in patients with sCR.

28 February 2017 in Cancer Science
Verified
Journal Article
Open access
PDF file
YSYasuhito Suehara
Yasuhito Suehara
HTHiroyuki Takamatsu
Hiroyuki Takamatsu
KFKota Fukumoto
Kota Fukumoto
MFManabu Fujisawa
Manabu Fujisawa
KNKentaro Narita
Kentaro Narita
KMKosei Matsue
Kosei Matsue
Immunoglobulin (Ig) heavy/light chain (HLC) assays enable the separate quantification of the different light chain types of each Ig class. We retrospectively analyzed the correlation of heavy/light chain ratio (HLCR) with clinical status and its impact on outcome in 120 patients with multiple myeloma (MM). Abnormal HLCR was seen more frequently in patients with poorer myeloma response, and it appeared to be more sensitive for detecting clonality in IgA myeloma compared to IgG myeloma after treatment. Among the 85 patients who achieved ≥VGPR, the patients remained HLCR abnormal were showed significantly shorter overall survival (OS) compared to those achieving a normal HLCR (not reached vs 55.5 months, P = 0.032). This correlation was seen in IgA myeloma patients (not reached vs 30.1 months, P = 0.014), but not in IgG myeloma patients when patients were analyzed separately. Univariate and multivariate analysis of factors that may affect survival identified abnormal HLCR at the best response as the only independent risk factor (hazard ratio, 4.7; 95% confidence interval, 1.4 – 15.26; P = 0.012) for shorter OS in this subset of patients. This study highlighted the HLC assay as a prognostic predictor in patients with IgA myeloma.